Evidencia científica

Todos los tests están avalados por una amplia evidencia científica. Te mostramos el detalle para cada uno de ellos.

CARDIO INCODE SCORE

Cardio inCode® Score is a genetic test for the evaluation of cardiovascular risk (the risk of having a coronary event in the next 10 years).

Genetics make a 50% contribution to the development of cardiovascular events, and there is a direct, linear association between the genetic load and the risk of coronary events (both incident and recurrent). Over 60% of cardiovascular events happen to patients classified in the groups of moderate and low risk, on the basis of classical cardiovascular risk factors.

The inclusion of genetic load in the assessment makes it possible to attain a more accurate, reliable overall cardiovascular risk score, and identify those patients at highest risk, for whom to adjust therapy and therapeutic goals to their new risk level. With Cardio inCode® Score, 5% of the patients in the low risk group and 14% of those in the moderate risk group were reclassified to higher risk categories (Iribarren et al., 2016).

GENES/VARIANTS ANALYZED AND ANALYSIS TECHNIQUE

The test analyzes 12 genetic variants of the Single Nucleotide Polymorphism (SNPs) type through the TaqManR chemical analysis from Life Technologies, with the Fluidigm genotyping platform. These genetic variants are associated with ischaemic heart disease and are independent from classical cardiovascular risk factors. These variants have been identified in Genome-Wide Association studies or GWAs.

PROFILE OF PATIENTS

  • Patients with classical cardiovascular risk factors
  • Patients with other risk factors (being overweight, obese, having hypertriglyceridaemia, etc.)
  • Patients with familial history of ischaemic heart disease, especially if in first-degree relatives and/or disease presented at young ages
  • As part of a general medical check-up

ADDITIONAL INFORMATION

Cardio inCode® Score is the only available genetic test for the assessment of cardiovascular risk that measures the patient’s genetic load and integrates it into the current risk estimate functions (Framingham, REGICOR or low risk score). This allows physicians to inform on cardiovascular risk with or without the genetic load, which may mean a reclassification of the patient into higher risk categories. What’s more, Cardio inCode Score is the only test that has been validated in over 70,000 individuals from different population groups (Spaniards, European-origin United States citizens, Latin Americans, African-Americans and Asians).

BIBLIOGRAPHY

Numerous scientific articles published in prestigious national and international journals have been written about Cardio inCode Score:

  • Rincón LM et al. A genetic risk score predicts recurrent events after myocardial infarction in young adults. Rev ESp Cardiol 2019. doi:/10.1016/j.rec.2019.08.006
  • Iribarren C et al. Weighted multi-marker genetic risk scores for incident coronary heart disease among individuals of African, Latino and East-Asian ancestry. Scientific Reports 2018;8:6853
  • Iribarren C et al. Clinical utility of multimarker genetic risk scores for prediction of incident heart disease. A cohort study among over 51000 individuals of European ancestry. Circ Cardiovasc Genet 2016;9:531-540
  • Doménech M et al. Awareness of genetic coronary risk score improves blood pressure control in hypertensive patients. Rev Esp Cardiol 2016;69(12):1119-1240
  • Ramírez de Arellano A et al. Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment. Appl Health Econ Health Policy 2013;11:531-542
  • Lluis-Ganella C et al. Assessment of the value of a genetic risk score in improving the estimation of coronary risk. Atherosclerosis 2012;222:456-463
  • Lluis-Ganella C et al. Additive effects of multiple genetic variants on the risk of coronary artery disease. Rev Esp Cardiol 2010;63(8):925-33.

CARDIO INCODE CHECK

Cardio inCode® Check is a genetic test for evaluation of cardiovascular risk (the risk of presenting a coronary event in the next 10 years) and a patient’s predisposition to cardiovascular risk factors.

Genetic predisposition plays a major role in both cardiovascular risk factors and coronary risk. Genetics make a 50% contribution to the development of cardiovascular events, and there is a direct, linear association between the genetic load and the risk of cardiovascular events (both incident and recurrent).

The inclusion of genetic load in the assessment makes it possible to attain a more accurate, reliable overall cardiovascular risk score, and identify those patients at highest risk, for whom to adjust therapy and therapeutic goals to their new risk level. On another note, knowing a patient’s genetic predisposition to cardiovascular risk factors makes it possible to establish preventive measures for those who have not developed them yet, be stricter with those who have predisposition and risk factors, and provide guidance to optimize factors in patients who do not have genetic predisposition.

GENES/VARIANTS ANALYZED AND ANALYSIS TECHNIQUE

The test analyzes 170 genetic variants of the Single Nucleotide Polymorphism (SNPs) type through the TaqManR chemical analysis from Life Technologies, with the Fluidigm genotyping platform. Twelve of these variants are associated with ischaemic heart disease and are independent from classical cardiovascular risk factors; these are the variants analyzed in the Cardio inCode® Score test. The remaining 158 variants are involved in the genetic predisposition to developing eight cardiovascular risk factors. All of these variants have been identified in Genome-Wide Association studies or GWAs.

PROFILE OF PATIENTS

  • Patients with classical cardiovascular risk factors
  • Patients with other risk factors (including being overweight, obese, having hypertriglyceridaemia, etc.)
  • Patients with familial history of ischaemic heart disease, especially if in first-degree relatives and/or disease presented at young ages
  • As part of a general medical check-up

ADDITIONAL INFORMATION

Cardio inCode® Check is the only available genetic test for the assessment of cardiovascular risk that measures the patient’s genetic load and integrates it into the current risk estimate functions (Framingham, REGICOR or low risk score) in addition to evaluating genetic predisposition to eight cardiovascular risk factors.

This allows physicians to inform on cardiovascular risk with or without the genetic load, which may mean a reclassification of the patient into higher risk categories.

Additionally, it is the only test that has been validated in over 70,000 individuals from different population groups (Spaniards, European-origin United States citizens, Latin Americans, African-Americans and Asians).

BIBLIOGRAPHY

Numerous scientific articles published in prestigious national and international journals have been written about Cardio inCode® Check:

  • Rincón LM et al. A genetic risk score predicts recurrent events after myocardial infarction in young adults. Rev ESp Cardiol 2019. doi:/10.1016/j.rec.2019.08.006
  • Iribarren C et al. Weighted multi-marker genetic risk scores for incident coronary heart disease among individuals of African, Latino and East-Asian ancestry. Scientific Reports 2018;8:6853
  • Iribarren C et al. Clinical utility of multimarker genetic risk scores for prediction of incident heart disease. A cohort study among over 51000 individuals of European ancestry. Circ Cardiovasc Genet 2016;9:531-540
  • Doménech M et al. Awareness of genetic coronary risk score improves blood pressure control in hypertensive patients. Rev Esp Cardiol 2016;69(12):1119-1240
  • Ramírez de Arellano A et al. Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment. Appl Health Econ Health Policy 2013;11:531-542
  • Lluis-Ganella C et al. Assessment of the value of a genetic risk score in improving the estimation of coronary risk. Atherosclerosis 2012;222:456-463
  • Lluis-Ganella C et al. Additive effects of multiple genetic variants on the risk of coronary artery disease. Rev Esp Cardiol 2010;63(8):925-33.

More information

Send us your details and request through this form and we will reply soon.

    GENinCode shall respond to requests for information, products and / or services and registration to events, as well as send commercial and legal communications deemed appropriate to the client. You may exercise your rights of access, rectification, cancellation, destruction or, opposition, or limit the treatment of data transfer at any time by notifying GENinCode - For further information please view our privacy policy here.